Amarin Corporation plc. is a rapidly growing, innovative biopharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. This focus includes a commitment to research and education in cardiovascular health.
High levels of quality, integrity and collaboration are embedded in Amarin’s culture. Amarin, through its dedicated team of professionals, constantly seeks to improve patient care through its actions and products while also striving to continuously improve along the way. By working together and supporting these efforts, inside and outside of the company, Amarin can empower, share and learn as it strides toward the unified goal of excellence—and beyond.
Prescription VASCEPA (icosapent ethyl), along with diet, is clinically proven to lower very high triglycerides in adults by 33%, without raising bad cholesterol (LDL-C).†
VASCEPA is FDA-approved and proven to work. Learn more >
|*||Vascepa 1-gram capsules contain 1 gram of icosapent ethyl, a form of the unique Omega-3 fatty acid known as EPA, and inactive ingredients.|
|†||In MARINE trial, on average, along with diet changes, adults with very high triglycerides experienced a 33% reduction without raising LDL-C vs. placebo. Individual results may vary.|